185 related articles for article (PubMed ID: 22376016)
1. ALL-BFM 95 treatment in Turkish children with acute lymphoblastic leukemia--experience of a single center.
Kocak U; Gursel T; Kaya Z; Aral YZ; Albayrak M; Keskin EY; Belen B; Isık M; Oner N
Pediatr Hematol Oncol; 2012 Mar; 29(2):130-40. PubMed ID: 22376016
[TBL] [Abstract][Full Text] [Related]
2. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
3. Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience.
Hazar V; Karasu GT; Uygun V; Akcan M; Küpesiz A; Yesilipek A
J Pediatr Hematol Oncol; 2010 Nov; 32(8):e317-22. PubMed ID: 20930649
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
5. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
Schrauder A; Reiter A; Gadner H; Niethammer D; Klingebiel T; Kremens B; Peters C; Ebell W; Zimmermann M; Niggli F; Ludwig WD; Riehm H; Welte K; Schrappe M
J Clin Oncol; 2006 Dec; 24(36):5742-9. PubMed ID: 17179108
[TBL] [Abstract][Full Text] [Related]
6. [Clinical features and prognosis of children with lymphoblastic lymphoma].
Jin L; Zhang R; Huang S; Yang J; Duan YL; Zhang YH
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):138-42. PubMed ID: 22780934
[TBL] [Abstract][Full Text] [Related]
7. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
Bajel A; George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
Pediatr Blood Cancer; 2008 Nov; 51(5):621-5. PubMed ID: 18688848
[TBL] [Abstract][Full Text] [Related]
8. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
Mora J; Filippa DA; Qin J; Wollner N
Cancer; 2003 Sep; 98(6):1283-91. PubMed ID: 12973853
[TBL] [Abstract][Full Text] [Related]
9. [Treatment failure in children with acute myelocytic leukemia: over 25-year experience of Polish Pediatric Leukemia/Lymphoma Study Group with four consecutive unified treatment protocols for childhood acute myelocytic leukemia].
Dłuzniewska A; Balwierz W; Balcerska A; Chybicka A; Kamieńska E; Karolczyk G; Karpińska-Derda I; Krawczuk-Rybak M; Kowalczyk JR; Lewandowska D; Maciejka-Kapuścińska L; Kołtano S; Malinowska I; Matysiak M; Mikołajczyk M; Mizia-Malarz A; Muszyńska-Rosłan K; Niedźwiedzki M; Pohorecka J; Sikorska-Fic B; Sobol G; Sońta-Jakimczyk D; Tomaszewska R; Urasiński T; Wachowiak J; Wieczorek M; Wójcik B; Wysocki M
Przegl Lek; 2010; 67(6):366-70. PubMed ID: 21344763
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.
Möricke A; Zimmermann M; Reiter A; Henze G; Schrauder A; Gadner H; Ludwig WD; Ritter J; Harbott J; Mann G; Klingebiel T; Zintl F; Niemeyer C; Kremens B; Niggli F; Niethammer D; Welte K; Stanulla M; Odenwald E; Riehm H; Schrappe M
Leukemia; 2010 Feb; 24(2):265-84. PubMed ID: 20010625
[TBL] [Abstract][Full Text] [Related]
11. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
[TBL] [Abstract][Full Text] [Related]
12. Prognosis and outcome of relapsed acute lymphoblastic leukemia: a Hong Kong Pediatric Hematology and Oncology Study Group report.
Leung AW; Vincent L; Chiang AK; Lee AC; Cheng FW; Cheuk DK; Luk CW; Ling SC; Li CK
Pediatr Blood Cancer; 2012 Sep; 59(3):454-60. PubMed ID: 22610685
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of infantile acute lymphoblastic leukemia with protocol ALL-BFM 83].
Aracil Santos FJ; Bernacer Borja M; López Pérez J; Melero Moreno C; Valverde Moreno F; Gil Gil C; Contra Gómez T; Martín Ramos N
An Esp Pediatr; 1989 Oct; 31(4):362-7. PubMed ID: 2627059
[TBL] [Abstract][Full Text] [Related]
14. Treatment of childhood acute lymphoblastic leukaemia with the BFM regimen.
Kudva GC; Chandy M; Raghupathy P; Dennison D; Srivastava A; Bhushan V; Singh R
Indian J Cancer; 1994 Jun; 31(2):78-85. PubMed ID: 7927453
[TBL] [Abstract][Full Text] [Related]
15. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
[TBL] [Abstract][Full Text] [Related]
16. Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. BFM Relapse Study Group.
Borgmann A; Hartmann R; Schmid H; Klingebiel T; Ebell W; Göbel U; Peters C; Gadner H; Henze G
Bone Marrow Transplant; 1995 Apr; 15(4):515-21. PubMed ID: 7655375
[TBL] [Abstract][Full Text] [Related]
17. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate--a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Pichler H; Reismüller B; Steiner M; Dworzak MN; Pötschger U; Urban C; Meister B; Schmitt K; Panzer-Grümayer R; Haas OA; Attarbaschi A; Mann G;
Br J Haematol; 2013 May; 161(4):556-65. PubMed ID: 23480776
[TBL] [Abstract][Full Text] [Related]
18. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
19. Treating childhood acute lymphoblastic leukemia in a developing country 1998-2003: the experience of a single children's hospital in China.
Gao YJ; Lu FJ; Wang HS
J Pediatr Hematol Oncol; 2006 Dec; 28(12):798-802. PubMed ID: 17164648
[TBL] [Abstract][Full Text] [Related]
20. Outcome of modified St Jude total therapy 13A for childhood acute lymphoblastic leukemia in the southeast region of Turkey.
Koc A; Aycicek A; Ozdemir ZC; Soker M; Varma M
J Pediatr Hematol Oncol; 2013 Jan; 35(1):36-41. PubMed ID: 23138117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
